齋藤　義正 （ サイトウ　ヨシマサ ）

Saito, Yoshimasa

写真a

所属（所属キャンパス）

薬学部 薬学科 薬物治療学講座 （ 芝共立 ）

職名

教授
このページの先頭へ▲
 

研究分野 【 表示 ／ 非表示 】

  • ライフサイエンス / 腫瘍診断、治療学

このページの先頭へ▲
 

著書 【 表示 ／ 非表示 】

  • Genes and Antiaging Medicine: Epigenetics and Antiaging

    Saito Y., Anti Aging Medicine Basics and Clinical Practice, 2025年01月

    　概要を見る

    Epigenetics refers to the chemical modifications to DNA and histones that control gene expression without changing the DNA base sequence, and these changes are usually inherited after cell division. Typical examples of epigenetic changes include DNA methylation and acetylation and methylation of histones. Also, while the general term for the information of the DNA base sequence is called the “genome,” the general term for the epigenetic information that modifies this genome is called the “epigenome.” DNA methylation is the only physiological modification in the genome of vertebrates. DNA methylation is a reaction in which a methyl group is added to the 5-position carbon atom of cytosine (C) in a 2-base sequence (CpG) arranged from the 5′ side of DNA in the order of cytosine (C), guanine (G), and is catalyzed by DNA methyltransferase (DNMT). Many gene promoter regions have clusters of CpG sequences called CpG islands (Fig. 18.1). In the promoter regions of genes that generally show active expression, DNA methylation is not observed, and histones are acetylated. On the other hand, when the ninth lysine residue (H3K9) of histone H3 is methylated, it recruits DNMT and histone deacetylase (HDAC), DNA is methylated, and histones are deacetylated. These modifications cause the chromatin structure to aggregate and gene expression to be inactivated (Fig. 18.1). Thus, changes in the epigenome play a role like a switch that controls the ON and OFF of gene expression.

  • 遺伝子診断と個別化医療.「ゲノム創薬科学」

    齋藤 義正, 裳華房, 2017年10月

    担当範囲: pp269-287

  • エピジェネティクスとアンチエイジング医学.「アンチエイジング医学の基礎と臨床」第3版.

    齋藤 義正, メジカルビュー社, 東京, 2015年09月

    担当範囲: pp42-44

  • Advanced Glycation End-products (AGEs)阻害薬がOLEFTラットの肝および脂肪組織に及ぼす影響. 「酸化ストレスと肝疾患 8巻」.

    木村真規、南雲まい、飯田陽子、山田華名、齋藤義正、齋藤英胤., 株式会社嵯峨野, 東京, 2012年09月

    担当範囲: pp67-72

  • 加齢と消化器系の変化.「高齢者用食品の開発と展望」.

    齋藤義正、齋藤英胤., シーエムシー出版, 東京, 2012年07月

    担当範囲: pp7-12

このページの先頭へ▲

論文 【 表示 ／ 非表示 】

  • Environmental factors in gastric carcinogenesis and preventive intervention strategies

    Tan Y., Matsuzaki J., Saito Y., Suzuki H.

    Genes and Environment 47 （ 1 ）  2025年12月

    ISSN  18807046

    　概要を見る

    Gastric cancer, a significant global health concern, arises from a complex interplay of genetic and environmental factors. Helicobacter pylori (H. pylori) infection is a major risk factor that can be mitigated through eradication strategies. Epstein-Barr virus (EBV) infection causes a distinct subtype of gastric cancer called EBV-associated gastric cancer. The gastric microbiome, a dynamic ecosystem, is also involved in carcinogenesis, particularly dysbiosis and specific bacterial species such as Streptococcus anginosus. Long-term use of proton pump inhibitors and potassium-competitive acid blockers also increases the risk of gastric cancer, whereas non-steroidal anti-inflammatory drugs including aspirin may have a protective effect. Smoking significantly increases the risk, and cessation can reduce it. Dietary factors such as high intake of salt, processed meats, and red meat may increase the risk, whereas a diet rich in fruits and vegetables may be protective. Extracellular vesicles, which are small membrane-bound structures released by cells, modulate the tumor microenvironment and may serve as biomarkers for risk stratification and as therapeutic targets in gastric cancer. This review highlights the multifaceted etiology of gastric cancer and its risk factors and emphasizes the importance of a multi-pronged approach to prevention including H. pylori eradication and modification of lifestyle factors, as well as the potential of microbiome-based and EV-based interventions. Further research is needed to refine risk stratification and to develop personalized prevention strategies.

  • Impact of strength training of large muscle groups on quality of life

    Takahashi T., Matsuzaki J., Enomoto T., Saito Y.

    Journal of Clinical Biochemistry and Nutrition 77 （ 3 ） 264 - 267 2025年11月

    ISSN  09120009

    　概要を見る

    Muscle-strengthening activities reduce the risk of various diseases and promote overall health. Physical activities targeting large muscle groups, such as weightlifting or resistance exercises, provide an additional health benefit. The present study investigated the relationship between strength training and health-related quality of life (HRQOL) through a cross-sectional study of 50 adults participating in large muscle group strengthening activities (LMG) and 50 adults who did not (NLMG). HRQOL was assessed using the SF-12v2 questionnaire, and sleep habits were assessed using the PSQI questionnaire. The LMG group had a significantly higher Role/Social component summary (RCS) score than the NLMG group (50.5 ± 7.2 vs 47.2 ± 8.3; respectively, p = 0.040). The physical component summary (PCS) and mental component summary (MCS) scores also tended to be higher in the LMG group than in the NLMG group (52.6 ± 8.4 vs 49.9 ± 10.2, respectively; p = 0.15 and 59.0 ± 7.9 vs 56.7 ± 6.0, respectively; p = 0.10). Linear regression analysis showed that a higher RCS score was significantly associated with LMG training, whereas higher PCS and MCS scores were associated with better sleep quality. These results suggest that strength training targeting large muscle groups may improve the social aspect of HRQOL, highlighting the potential benefits of incorporating such exercises into regular physical activity regimens.

  • Association of KRAS variants with survival and therapeutic outcomes in biliary tract cancers

    Iida K., Matsui Y., Urabe Y., Muramatsu T., Matsuzaki J., Saito Y.

    ESMO Open 10 （ 6 ）  2025年06月

    　概要を見る

    Background: Biliary tract cancer (BTC) remains a highly aggressive malignancy with limited treatment options and poor prognosis. To explore the association between KRAS variants and survival/therapeutic outcomes of patients with BTC, we analyzed genetic and clinical data obtained from BTC patients who underwent comprehensive genomic profiling (CGP) testing in Japan. Patients and methods: A total of 7773 patients with BTC who were registered in the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) were included in this study. The main outcome was overall survival (OS) in months. For survival analysis, OS was measured from diagnosis to last follow-up or death, and for therapeutic outcomes, from treatment initiation to last follow-up or death. Results: The overall frequency of KRAS mutations in BTC was 23.4%. When classified according to tumor subtype, KRAS mutations were identified in 24.9% of patients with intrahepatic cholangiocarcinoma (IHC), in 32.2% of those with extrahepatic cholangiocarcinoma (EHC), and in 9.4% of those with gall-bladder cancer (GB). Among patients with KRAS mutations, G12D mutation was the most common in IHC (41.5%), EHC (35.9%), and GB (29.8%). In all BTC subtypes (IHC, EHC, and GB), patients with KRAS mutations had worse OS compared to those with wild-type KRAS. By KRAS variant, the G12D, G12V, and Q61H mutations were associated with poor OS in patients with IHC, while the G12D and G12V mutations were associated with poor OS in patients with EHC. Furthermore, in patients with unresectable BTC who received first-line treatment with regimens including gemcitabine, cisplatin, and durvalumab therapy, the G12D mutation was associated with poor OS across all regimens evaluated in this study. Conclusions: KRAS variants were significantly associated with poor prognosis and unfavorable therapeutic outcomes in BTC patients and may serve as potential prognostic and predictive factors.

  • Upper gastrointestinal triple stenosis in a patient with trisomy 17p syndrome: Case report and literature review

    Ando H., Mori H., Takabayashi K., Matsuura N., Masaoka T., Matsuzaki J., Saito Y., Kato M., Kosaki K., Kanai T.

    DEN Open 5 （ 1 ）  2025年04月

    ISSN  2692-4609

    　概要を見る

    Upper gastrointestinal stenosis, which can be congenital or acquired, can lead to dysphagia. The association between trisomy 17p syndrome, a rare chromosomal abnormality, and upper gastrointestinal stenosis is unclear. A 20-year-old man diagnosed with trisomy 17p syndrome was referred to our department due to recurrent vomiting. Esophagogastroduodenoscopy revealed stenotic areas in the esophagus, stomach, and duodenum. The congenital gastrointestinal stenosis present in both the duodenum and esophagus suggested that the stasis and reflux of digestive fluids exacerbated stenosis in the stomach and esophagus. Gastric acid suppression therapy and endoscopic dilation of the esophagus and duodenum effectively resolved the patient's vomiting symptoms.

  • Clinical applications of human organoids

    Verstegen M.M.A., Coppes R.P., Beghin A., De Coppi P., Gerli M.F.M., de Graeff N., Pan Q., Saito Y., Shi S., Zadpoor A.A., van der Laan L.J.W.

    Nature Medicine 31 （ 2 ） 409 - 421 2025年02月

    ISSN  10788956

    　概要を見る

    Organoids are innovative three-dimensional and self-organizing cell cultures of various lineages that can be used to study diverse tissues and organs. Human organoids have dramatically increased our understanding of developmental and disease biology. They provide a patient-specific model to study known diseases, with advantages over animal models, and can also provide insights into emerging and future health threats related to climate change, zoonotic infections, environmental pollutants or even microgravity during space exploration. Furthermore, organoids show potential for regenerative cell therapies and organ transplantation. Still, several challenges for broad clinical application remain, including inefficiencies in initiation and expansion, increasing model complexity and difficulties with upscaling clinical-grade cultures and developing more organ-specific human tissue microenvironments. To achieve the full potential of organoid technology, interdisciplinary efforts are needed, integrating advances from biology, bioengineering, computational science, ethics and clinical research. In this Review, we showcase pivotal achievements in epithelial organoid research and technologies and provide an outlook for the future of organoids in advancing human health and medicine.

全件表示 >>

このページの先頭へ▲

KOARA（リポジトリ）収録論文等 【 表示 ／ 非表示 】

全件表示 >>

このページの先頭へ▲

総説・解説等 【 表示 ／ 非表示 】

  • 胆道・膵臓がんオルガノイドを用いた個別化医療の実現に向けて

    齋藤義正

    医学のあゆみ 286 （ 7, 8 ） 649 - 652 2023年08月

    記事・総説・解説・論説等（学術雑誌）, 単著

  • がんオルガノイドー創薬・個別化医療の革新的プレクリニカルモデルとして

    齋藤義正

    医学のあゆみ 286 （ 7, 8 ） 623 2023年08月

    記事・総説・解説・論説等（学術雑誌）, 単著

  • 腸管上皮オルガノイドを用いたステムセルエイジング研究

    齋藤義正

    ファルマシア 56 （ 11 ） 994 - 998 2020年11月

    記事・総説・解説・論説等（学術雑誌）, 単著

  • Publisher Correction: Epigenetic silencing of Lgr5 induces senescence of intestinal epithelial organoids during the process of aging (npj Aging and Mechanisms of Disease, (2018), 4, 1, (12), 10.1038/s41514-018-0031-5)

    Uchida R., Saito Y., Nogami K., Kajiyama Y., Suzuki Y., Kawase Y., Nakaoka T., Muramatsu T., Kimura M., Saito H.

    npj Aging and Mechanisms of Disease （npj Aging and Mechanisms of Disease）  5 （ 1 ）  2019年12月

    　概要を見る

    © 2019, The Author(s). The original version of this Article had an incorrect Article number of 1, an incorrect Volume of 5 and an incorrect Publication year of 2019. These errors have now been corrected in the PDF and HTML versions of the Article.

  • ヘリコバクター・ピロリ感染症とmicroRNA発現異常.

    齋藤義正, 鈴木秀和, 齋藤英胤.

    細胞 （ニューサイエンス社）  44(10)   6-9 2012年09月

    記事・総説・解説・論説等（学術雑誌）, 共著

このページの先頭へ▲

研究発表 【 表示 ／ 非表示 】

  • 腸管上皮オルガノイドを用いたシングルセル解析により見えてきたこと

    齋藤義正

    [国内会議]  日本生理学会 第100回記念大会, 

    2023年03月
    , 

    口頭発表（招待・特別）

  • 誘導性CRISPR/dCas9を用いたC19MCの肝内胆管癌オルガノイドの分化における役割の解明

    葉 子祥、松崎 潤太郎、及川 千尋、金井 弥栄、齋藤 義正

    [国内会議]  第81回 日本癌学会学術総会, 

    2022年09月
    -
    2022年10月
    , 

    口頭発表（一般）

  • 膵がんドライバー遺伝子変異誘導による形質変化の追跡

    及川 千尋、松崎 潤太郎、落谷 孝広、齋藤 義正

    [国内会議]  第81回 日本癌学会学術総会, 

    2022年09月
    -
    2022年10月
    , 

    口頭発表（一般）

  • 難治性がんオルガノイドを用いた個別化医療の開発

    齋藤義正

    [国内会議]  第4回Cell Based Assay Workshop, 

    2022年03月
    , 

    口頭発表（招待・特別）

  • 胆道がん患者由来オルガノイドの樹立と創薬研究への応用

    齋藤義正

    [国内会議]  患者由来がんモデル研究会2021, 

    2021年12月
    , 

    口頭発表（招待・特別）

全件表示 >>

このページの先頭へ▲

競争的研究費の研究課題 【 表示 ／ 非表示 】

  • 国際協力による難治性がんオルガノイドライブラリーの構築

    2024年09月
    -
    2027年03月

    齋藤 義正, 国際共同研究加速基金（海外連携研究）, 補助金,  研究代表者

  • デザイナーエクソソームとオルガノイドを用いた個別化がん免疫療法の開発

    2024年06月
    -
    2026年03月

    齋藤 義正, 挑戦的研究（萌芽）, 補助金,  研究代表者

  • 胆道がん腫瘍微小環境の再構築による次世代オルガノイドの開発

    2024年04月
    -
    2027年03月

    齋藤 義正, 基盤研究(B), 補助金,  研究代表者

  • 抗真菌薬を基盤とした胆道・膵臓がんに対する新規治療薬の創製

    2020年04月
    -
    2023年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 齋藤 義正, 基盤研究(B), 補助金,  研究代表者

  • NAD+およびエピゲノムの制御による老化メカニズムの解明と新たな抗加齢介入の開発

    2019年06月
    -
    2021年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 齋藤　義正, 挑戦的研究（萌芽), 補助金,  研究代表者

全件表示 >>

このページの先頭へ▲

知的財産権等 【 表示 ／ 非表示 】

  • がん幹細胞集団の調製方法、異種移植片の調製方法、スクリーニング方法、ｍｉＲ－３４ａの発現量を低下させる方法及びがん幹細胞増殖抑制剤

    出願日： 特願2015-142164  2015年07月 

    特許権, 共同

このページの先頭へ▲

受賞 【 表示 ／ 非表示 】

  • Asian Pacific Digestive Week 2018, Emerging Leader Lectureship

    2018年11月

    受賞区分： 国際学会・会議・シンポジウム等の賞

  • 第18回日本抗加齢医学会総会　最優秀演題賞

    齋藤義正, 2018年05月, 腸管上皮オルガノイドを用いたステムセルエイジングの検討

    受賞区分： 国内学会・会議・シンポジウム等の賞

  • 日本抗加齢医学会優秀演題賞　

    木村真規、井手晴香、白井栄里奈、内田諒英、齋藤義正、齋藤英胤.　, 2016年06月, 第16回 日本抗加齢医学会総会, 高脂肪食摂取時の脂肪組織における老化マーカー遺伝子の発現変化とDNAメチル化阻害薬の効果.　

    受賞区分： 国内学会・会議・シンポジウム等の賞

    　説明を見る

    プログラム・抄録集: 170, 2016/6/10/12.

  • 日本抗加齢医学会優秀演題賞　

    内田諒英、齋藤義正、中岡哉彰、村松俊英、木村真規、齋藤英胤.　, 2016年06月, 第16回 日本抗加齢医学会総会　プログラム・抄録集: 174, 2016/6/10/12., オルガノイド培養法により樹立した腸管上上皮幹細胞における stem cell aging の検討.　

    　説明を見る

    プログラム・抄録集: 174, 2016/6/10/12.

  • 慶應義塾大学薬学部学部長賞

    2015年

    受賞区分： 塾内表彰等

全件表示 >>

このページの先頭へ▲
 

担当授業科目 【 表示 ／ 非表示 】

  • 課題研究（薬物治療学）

    2025年度

  • 大学院特別講義Ⅱ

    2025年度

  • 大学院特別講義Ａ

    2025年度

  • 演習（薬物治療学）

    2025年度

  • 卒業研究１（薬学科）

    2025年度

全件表示 >>

このページの先頭へ▲